Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=-abstract
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-abstract", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=-abstract", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=-abstract", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=-abstract" }, "data": [ { "type": "Grant", "id": "8498", "attributes": { "award_id": "1U01OH012275-01", "title": "Severity and long-term health effects of COVID-19 among World Trade Center responders", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24208, "first_name": "JAMES", "last_name": "YIIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-07-01", "end_date": "2026-06-30", "award_amount": 598578, "principal_investigator": { "id": 24260, "first_name": "MICHAEL Anthony", "last_name": "CRANE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1415, "ror": "", "name": "STATE UNIVERSITY NEW YORK STONY BROOK", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24261, "first_name": "Laura", "last_name": "Crowley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 24262, "first_name": "BENJAMIN J", "last_name": "LUFT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 24263, "first_name": "Olga", "last_name": "Morozova", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1415, "ror": "", "name": "STATE UNIVERSITY NEW YORK STONY BROOK", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Since late 2019, SARS-CoV-2 virus, and a resulting, potentially deadly disease called COVID-19, have caused a global pandemic. SARS-CoV-2 primarily causes disease in lungs but can also cause gastrointestinal and neurological disease. The majority of SARS-CoV-2 infections are mild, however people of older age and people with certain pre-existing conditions are at increased risk of severe illness and death. Emerging evidence suggests that genetic factors may also contribute to COVID-19 severity. While most infections completely resolve within several weeks, some people continue experiencing COVID-19 symptoms for weeks or even months after recovering from acute illness. Of major concern is an emerging evidence that even those who recover from symptomatic COVID-19 and even those who had a mild disease, may experience serious long-term complications affecting different body organs. Some of these complications include respiratory, cardiovascular, renal, neurological, and psychiatric conditions. Importantly, many potential long-term effects of COVID-19, as well as risk factors for long-term complications, remain unknown. Men and women who worked as first responders during the tragic 9/11/2001 World Trade Center (WTC) events constitute an aging population. Toxic exposures at the WTC sites caused a disproportionally high prevalence of certain health conditions (designated as WTC-related conditions) in this population, many of which have either been identified or are hypothesized to be risk factors for severe COVID-19 disease and may increase the likelihood of developing long-term complications. New York City (NYC) area, including Long Island, suffered from a major early SARS-CoV-2 outbreak, with an estimated 19-23% of the general population being infected in NYC. Pilot data from Long Island WTC Health Program suggest that about 10% of WTC responders in this area may have been infected. This research project aims to: 1) Assess the impact of SARS-CoV-2 infection, COVID-19 disease, and mandatory social distancing measures on short- and long-term physical and mental health outcomes among WTC responders; 2) Investigate demographic, health, and occupational risk factors, as well as the impact of toxic WTC exposures on COVID-19 disease severity and negative health outcomes following SARS-CoV-2 infection, and 3) Investigate genetic risk factors for COVID-19 disease severity and negative post-COVID outcomes. We hypothesize that in this population SARS-CoV-2 infection will exacerbate incidence and progression of respiratory, cardiovascular, and mental health conditions, and that similar demographic, health, genetic, occupational, and toxic exposure factors will be associated with increased risk of severe disease and long-term complications. The results of this study will help to better understand the impact of COVID-19 on WTC responders, identify sub-populations at increased risk of negative outcomes, and inform targeted interventions to manage these risks. Some of the study findings, in particular occupational and genetic risk factors of negative COVID-19 outcomes, will have broader implications beyond WTC responder population.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9892", "attributes": { "award_id": "5U01OH012275-02", "title": "Severity and long-term health effects of COVID-19 among World Trade Center responders", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24208, "first_name": "JAMES", "last_name": "YIIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-07-01", "end_date": "2026-06-30", "award_amount": 580572, "principal_investigator": { "id": 24262, "first_name": "BENJAMIN J", "last_name": "LUFT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1415, "ror": "", "name": "STATE UNIVERSITY NEW YORK STONY BROOK", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Since late 2019, SARS-CoV-2 virus, and a resulting, potentially deadly disease called COVID-19, have caused a global pandemic. SARS-CoV-2 primarily causes disease in lungs but can also cause gastrointestinal and neurological disease. The majority of SARS-CoV-2 infections are mild, however people of older age and people with certain pre-existing conditions are at increased risk of severe illness and death. Emerging evidence suggests that genetic factors may also contribute to COVID-19 severity. While most infections completely resolve within several weeks, some people continue experiencing COVID-19 symptoms for weeks or even months after recovering from acute illness. Of major concern is an emerging evidence that even those who recover from symptomatic COVID-19 and even those who had a mild disease, may experience serious long-term complications affecting different body organs. Some of these complications include respiratory, cardiovascular, renal, neurological, and psychiatric conditions. Importantly, many potential long-term effects of COVID-19, as well as risk factors for long-term complications, remain unknown. Men and women who worked as first responders during the tragic 9/11/2001 World Trade Center (WTC) events constitute an aging population. Toxic exposures at the WTC sites caused a disproportionally high prevalence of certain health conditions (designated as WTC-related conditions) in this population, many of which have either been identified or are hypothesized to be risk factors for severe COVID-19 disease and may increase the likelihood of developing long-term complications. New York City (NYC) area, including Long Island, suffered from a major early SARS-CoV-2 outbreak, with an estimated 19-23% of the general population being infected in NYC. Pilot data from Long Island WTC Health Program suggest that about 10% of WTC responders in this area may have been infected. This research project aims to: 1) Assess the impact of SARS-CoV-2 infection, COVID-19 disease, and mandatory social distancing measures on short- and long-term physical and mental health outcomes among WTC responders; 2) Investigate demographic, health, and occupational risk factors, as well as the impact of toxic WTC exposures on COVID-19 disease severity and negative health outcomes following SARS-CoV-2 infection, and 3) Investigate genetic risk factors for COVID-19 disease severity and negative post-COVID outcomes. We hypothesize that in this population SARS-CoV-2 infection will exacerbate incidence and progression of respiratory, cardiovascular, and mental health conditions, and that similar demographic, health, genetic, occupational, and toxic exposure factors will be associated with increased risk of severe disease and long-term complications. The results of this study will help to better understand the impact of COVID-19 on WTC responders, identify sub-populations at increased risk of negative outcomes, and inform targeted interventions to manage these risks. Some of the study findings, in particular occupational and genetic risk factors of negative COVID-19 outcomes, will have broader implications beyond WTC responder population.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15385", "attributes": { "award_id": "1K08AI181642-01A1", "title": "Cost-Effectiveness of HIV Testing in U.S. Emergency Departments", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6828, "first_name": "Rosemary G", "last_name": "McKaig", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-19", "end_date": "2029-06-30", "award_amount": 192672, "principal_investigator": { "id": 31985, "first_name": "Christopher L", "last_name": "Bennett", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Roughly 1 in 8 Americans living with HIV are unaware of their infection. As an entry point into the healthcare system, emergency departments (EDs) are uniquely positioned to help reduce this burden of undiagnosed HIV in the U.S. A growing amount of all healthcare in the U.S. is delivered in an ED setting. Unfortunately, compared with other settings, EDs have some of the lowest HIV testing rates. These rates further declined leading up to the COVID-19 pandemic and despite renewed efforts in the Ending the HIV Epidemic in the U.S. (EHE) initiative. Decreasing testing rates appear to stem from several barriers, including concerns about cost and the impact of increased testing on overcrowding and boarding. Unfortunately, few studies have focused on exploring these barriers, either since EHE’s launch or following the COVID-19 pandemic. The primary purpose of this award is to provide Dr. Christopher Bennett, Assistant Professor of Emergency Medicine at Stanford University, the support necessary to facilitate their long-term goals to (1) help EDs lead the charge in ending the HIV epidemic in the U.S. and (2) transition from a junior investigator to an independent physician–scientist with expertise in economic analyses, implementation science, and qualitative methods. In Aim 1, Dr. Bennett will train in economic analyses to investigate the cost-effectiveness of ED-based HIV screening in geographic areas targeted by EHE compared against current screening rates and then determine the incremental cost-effectiveness of HIV screening in all U.S. EDs. In Aims 2 and 3, the candidate will innovatively leverage a recent California initiative in which 28 local EDs received funding to implement or expand routine, opt-out HIV screening. Specifically, in Aim 2, Dr. Bennett will train in implementation science to create a typology of the screening strategies used by these EDs; this work will be informed by a stakeholder group of ED leaders with efforts guided by the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework. In Aim 3, Dr. Bennett will obtain additional training in qualitative methods to employ semi-structured interviews of a diverse cohort – frontline ED providers implementing HIV screening and persons tested for HIV at these EDs – at a subset of these sites to illuminate firsthand barriers and facilitators encountered during the real-world implementation of HIV screening programs, guided by the updated Consolidated Framework for Implementation Research (CFIR). This K08 award is designed to leverage Dr. Bennett’s clinical training and build upon their background in epidemiology and health services research. This innovative K08 responds to several NIH priorities for HIV and HIV-related research and will aid decision makers in identifying which strategies work for different communities. Overall, this work will advance EHE’s mission to make HIV screening routine in all settings that serve a high volume of racial, ethnic, sexual, and gender minority groups, with focused approaches to enable testing for more people at risk for HIV.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11090", "attributes": { "award_id": "1U01DK134996-01", "title": "Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [ { "id": 6382, "first_name": "MIRANDA MARGUERITE", "last_name": "Broadney", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-03-10", "end_date": "2029-01-31", "award_amount": 166817, "principal_investigator": { "id": 27062, "first_name": "Amy Debra", "last_name": "Fleischman", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [ { "id": 27063, "first_name": "Elvira Marie", "last_name": "Isganaitis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 27064, "first_name": "Takara Leah", "last_name": "Stanley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1642, "ror": "https://ror.org/0280a3n32", "name": "Joslin Diabetes Center", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ Abstract Rising obesity has led to an unprecedented increase in pre-diabetes (preD) and type 2 diabetes (T2D) incidence in children and adolescents, a worrisome trend amplified by the COVID 19 pandemic. Based on current evidence, it remains difficult to predict whether children and adolescents with preD will progress to T2D. Our proposal aims to address key questions in the pathogenesis of T2D, focusing on modifiable risk factors. Leveraging a collaboration between Boston Children’s Hospital, Joslin Diabetes Center, and Massachusetts General Hospital, in partnership with community health centers in the Greater Boston area, we propose to recruit a diverse cohort of early pubertal youth (ages 7-15, n=300) with preD, elevated BMI (≥95th percentile), a positive family history of diabetes, and one or more additional risk factors. We propose to combine rigorous annual clinical studies with convenient remote assessments, to gain a granular understanding of metabolic, hormonal and environmental factors contributing to T2D pathogenesis. In Aim 1, we will test whether measures of glucose homeostasis and beta cell function differ between youth with preD who progress to T2D versus those who revert to normoglycemia or remain preD. We propose to analyze glycemia and beta cell function using oral GTT and incretin hormone levels, and assessments adaptable to community settings, e.g., continuous glucose monitors and home A1c kits. In Aim 2, we will test whether fitness level and amount of physical activity differ between youth with preD who progress to T2D versus those who revert to normoglycemia or remain preD. We propose to evaluate fitness level using detailed clinical assessments, including VO2 max, assessments adaptable to community settings including grip strength, and free-living assessments using wearables and app-based activity tracking. In Aim 3, we will test whether evolution of body composition during growth and puberty predicts progression to T2D. We propose to analyze body composition (total and visceral fat) using DXA, and hepatic fat using echography-based assessments, gonadal hormones, adrenal androgens, and mediators of growth hormone action, as well as assessments adaptable to community settings, e.g., BMI and app-based dietary surveys. As secondary aims, we propose to create a data repository to allow evaluation of social and environmental factors contributing to T2D onset at a consortium level, with measures including social determinants of health, neighborhood and geographic characteristics (using geocoding techniques), and the environmental exposome. We also propose the creation of a biological repository to allow multi-omics studies to identify genomic, epigenetic, and/or metabolomic markers for progression from preD to T2D in youth at a consortium level. We propose to collect a rich biorepository of longitudinal samples (i.e., plasma, PBMCs, urine, stool, hair) from all participants that will set the stage for future systems biology-driven studies. Together, these studies will permit development of a predictive model based on variables easily measurable at the community level, which can then be applied to the detection and treatment of youth at highest risk of T2D.", "keywords": [ "Address", "Adolescent", "Adrenal Glands", "Adult", "Affect", "Age", "Androgens", "Area", "B-Lymphocytes", "Basal metabolic rate", "Beta Cell", "Biological", "Blood Vessels", "Body Composition", "Body mass index", "Boston", "COVID-19 pandemic", "Cell physiology", "Characteristics", "Child", "Childhood", "Clinical", "Clinical Research", "Clinical assessments", "Collaborations", "Color", "Communities", "Data", "Data Collection", "Detection", "Development", "Diabetes Mellitus", "Diagnosis", "Diet Surveys", "Disease", "Dual-Energy X-Ray Absorptiometry", "Early Diagnosis", "Environmental Risk Factor", "Epigenetic Process", "Evaluation", "Evolution", "Family history of", "Fatty acid glycerol esters", "Feces", "Future", "General Hospitals", "Genomics", "Geography", "Glare", "Glucose", "Glycosylated hemoglobin A", "Gonadal Hormones", "Growth", "Hair", "Hand Strength", "Hepatic", "Home", "Hormonal", "Hormones", "Hyperglycemia", "Impairment", "Incidence", "Insulin Resistance", "Insulin-Like Growth Factor I", "Light", "Massachusetts", "Measurable", "Measures", "Mediator", "Metabolic", "Neighborhood Health Center", "Neighborhoods", "Non-Insulin-Dependent Diabetes Mellitus", "Obesity", "Oral", "Participant", "Pathogenesis", "Pediatric Hospitals", "Peripheral Blood Mononuclear Cell", "Phenotype", "Physical activity", "Physiological", "Plasma", "Prediabetes syndrome", "Prevention", "Puberty", "Public Health", "Research", "Risk", "Risk Factors", "Risk Reduction", "Running", "Sampling", "Shapes", "Somatotropin", "Stress", "Systems Biology", "Techniques", "Testing", "Triglycerides", "Ultrasonography", "Urine", "VO2max", "Visceral fat", "Youth", "actigraphy", "biobank", "blood glucose regulation", "clinical center", "cohort", "community setting", "data repository", "diabetes pathogenesis", "fasting plasma glucose", "fitness", "glucose monitor", "high body mass index", "high risk", "incretin hormone", "indexing", "insulin secretion", "insulin sensitivity", "macrovascular disease", "marginalized community", "marginalized population", "metabolomics", "modifiable risk", "multiple omics", "predictive marker", "predictive modeling", "prevent", "progression marker", "recruit", "remote assessment", "repository", "sample collection", "social factors", "social health determinants", "trend", "type 2 diabetes in children", "ultrasound", "waist circumference" ], "approved": true } }, { "type": "Grant", "id": "15376", "attributes": { "award_id": "1R43HL172484-01", "title": "A novel mobile phone technology to improve access for preeclampsia and hypertension detection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 25676, "first_name": "JASMINA", "last_name": "Varagic", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-20", "end_date": "2025-08-31", "award_amount": 292897, "principal_investigator": { "id": 31977, "first_name": "John conrad", "last_name": "Heironimus", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28353, "first_name": "Martin Richard", "last_name": "Huecker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28354, "first_name": "David", "last_name": "Wolfson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2096, "ror": "", "name": "TELE-STETHOSCOPE INC.", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "/ Abstract Preeclampsia is a complication affecting 2 – 8% of all pregnancies and results in significant maternal and neonatal morbidity and mortality. The invention to be researched in this grant detects preeclampsia and hypertension in patients with the phones that they already own. It improves outcomes by increasing access to care among underserved populations and monitoring frequency among high risk patients. Patients record themselves using their own phones which takes only a few minutes. The long term objective is to commercialize a product which enables any of 7 billion phones to assist in preeclampsia or gestational hypertension detection. The invention is intended to be used at home by patients via a phone app with results sent to the prescribing obstetrician (OB). The purpose is to alert the OB if immediate physical examination is needed and to initiate possible preeclampsia management protocol. In these situations, there are no other comparable testing options. The invention includes both improvements to clinical practice and to science. Current clinical practice standard of care requires patients to be examined in an OB office. The invention allows preeclampsia and hypertension to be detected via patient self-examination from locations outside the OB office. This improves upon current technology such as home blood pressure cuffs and in-office dipstick urinalysis. In terms of improvements to science, the invention consists of both a Universal Translator (UT) and Deductive Intelligence (DI). UT allows for any mobile phone to capture body acoustic data. DI is a novel physics based approach to creating classifier algorithms from passively received time series data, such as mobile phone recordings received from the UT. The invention analyzes hemodynamics and extracts pertinent physics based features from which a classifier algorithm is based. This will be the third large scale human study that demonstrates classification of cardio - pulmonary functionality. It follows a published study on COVID detection as well as a study under peer review on the ability to reproduce echocardiogram estimates of ejection fraction. The echocardiogram study establishes the protocol to be used in the proposed research. In a recent preliminary study, 46 pregnant women were recorded at the aortic site. The resulting model was able to determine which patients had high blood pressure and to accurately determine which patients had complications. These studies support our hypothesis that acoustic hemodynamic data captured by OEM phone microphones, at the aortic auscultation site and at the upper arm, can be used to identify patients who have preeclampsia and/or hypertension. The study has two primary aims. The first is to demonstrate proof of concept that the invention enables ordinary mobile phones to reproduce physicians’ diagnosis of pre-eclampsia. The second aim is to demonstrate proof of concept that the invention enables ordinary mobile phones to reproduce cuff measurements of blood pressure and to detect hypertension. The approach is based on recruitment from both outpatient clinics and inpatient hospital settings. Patients already labeled with preeclampsia or high blood pressure will be enrolled as well as control patients without disease conditions. Patients will be recorded by clinicians with a custom phone app. Algorithms will be developed based on these recordings using UT and DI. Results will be tested and analyzed using AUC, sensitivity/specificity, accuracy as well adj RSQ for the linear regression analysis. The team consists of a broad range of talent including the inventor of the technology, the Maternal Fetal Medicine Division Director at the hospital, the research director of emergency medicine for the hospital running the tests, statistical expertise, and project management.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7436", "attributes": { "award_id": "3U01AA020780-10S1", "title": "URBAN ARCH 4/5 Russia Cohort-Targeting HIV-comorbidities with Pharmacotherapy to Reduce Alcohol and Tobacco Use in HIV-infected Russians", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Alcohol Abuse and Alcoholism (NIAAA)" ], "program_reference_codes": [], "program_officials": [ { "id": 9113, "first_name": "Joe", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2011-09-20", "end_date": "2022-08-31", "award_amount": 186966, "principal_investigator": { "id": 20671, "first_name": "MATTHEW S", "last_name": "FREIBERG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1220, "ror": "https://ror.org/010b9wj87", "name": "Boston Medical Center", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 20672, "first_name": "JEFFREY H.", "last_name": "SAMET", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 20673, "first_name": "Hilary A", "last_name": "Tindle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1220, "ror": "https://ror.org/010b9wj87", "name": "Boston Medical Center", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Over 4,000,000 people worldwide are infected with COVID19 and cases are rising. Acute respiratory infections (e.g., Severe Acute Respiratory Virus), are associated with increased cardiovascular disease (CVD) risk, and early data indicate that COVID19 is associated with higher CVD risk. People living with HIV (PLWH) also have increased CVD risk compared to uninfected people and this risk is highest among those who are hazardous drinkers and smokers. Our research is designed to reduce CVD risk among these high risk PLWH and to elucidate key mechanism(s). St PETER HIV (U01AA020780) is a randomized controlled trial in St. Petersburg, Russia comparing the effects of nicotinic partial agonists on alcohol consumption, smoking, and inflammation and CVD risk among PWLH who are heavy drinkers and smokers. The Alcohol associated Comorbidity and Microbiome Evaluation (ACME ½ U01AA026222) study, nested within St PETER HIV, examines the gut microbiome as a novel pathway for increased CVD risk among these PLWH. HIV infection and hazardous drinking both cause microbial translocation, which increases systemic inflammation and leads to CVD. Whether COVID19 co-infection among PLWH who drink and smoke increases inflammation, alters the gut microbiome (i.e., reduces beneficial butyrate-producing bacteria which protect the gut from microbial translocation) and by extension alters the plasma metabolome (e.g., reduces plasma butyrate levels) is unknown. Sparse data describe the prevalence of COVID19 among PLWH who are heavy drinkers and smokers, and no data exist assessing the association between COVID19 and biomarker levels of inflammation and the plasma metabolome (e.g., butyrate) in this population. Our overarching hypothesis is that COVID19 is a CVD risk factor among heavy drinking and smoking PLWH. For this application, we hypothesize that COVID19 infection will be: (1) common among St PETER HIV participants; (2) associated with increased inflammation (e.g., higher IL-6); and (3) associated with an unfavorable metabolomic profile (i.e., lower plasma butyrate) as compared to those not infected with COVID19. To test our hypotheses, we will leverage existing data from and collect new data among St PETER HIV and ACME 1/2 participants including alcohol measures using the timeline follow-back; biomarkers of inflammation, data on comorbid conditions, longitudinal stored blood and fecal samples and imaging data. New data will include: COVID19 survey items and testing, alcohol and smoking data, and inflammatory/metabolomic biomarker testing. We will leverage these data to complete Aim 1: to describe and estimate prevalence of COVID19 infection in the St PETER HIV cohort; Aim 2: to determine the association between COVID19 infection and biomarkers of systemic inflammations; and Aim 3 (exploratory) to determine metabolic profiles among heavy drinking and smoking PLWH. Completing these aims will advance understanding of COVID19 effects on innate immune function and the plasma metabolome. Results will inform future interventions targeting the GI microbiome among PLWH.", "keywords": [ "Acute", "Acute respiratory infection", "Agonist", "Alcohol consumption", "Alcohol or Other Drugs use", "Alcoholic beverage heavy drinker", "Alcohols", "Atherosclerosis", "Back", "Bacteria", "Biological Assay", "Biological Markers", "Blood", "Blood specimen", "Butyrates", "C-reactive protein", "COVID-19", "Cardiovascular Diseases", "Data", "Development", "Echocardiography", "Epidemiology", "Equilibrium", "Evaluation", "Future", "HIV", "HIV Infections", "HIV-1", "Heavy Drinking", "Hepatic", "Image", "Infection", "Inflammation", "Inflammatory", "Innate Immune Response", "Interleukin-6", "Intervention", "Intervention Trial", "Intestinal permeability", "Laboratories", "Literature", "Measures", "Participant", "Pathway interactions", "Pharmacotherapy", "Plasma", "Population", "Prevalence", "RNA", "Randomized Controlled Trials", "Reporting", "Research", "Risk", "Risk Factors", "Role", "Russia", "Sampling", "Smoke", "Smoker", "Smoking", "Specimen", "Statistical Data Interpretation", "Surveys", "Testing", "Time", "TimeLine", "Tobacco use", "Visit", "Volatile Fatty Acids", "Work", "cardiovascular disorder risk", "cardiovascular risk factor", "cigarette smoking", "co-infection", "cohort", "comorbidity", "coronavirus disease", "cytisine", "cytokine", "design", "gut microbiome", "hazardous drinking", "high risk", "innate immune function", "intestinal fatty acid binding protein", "metabolic profile", "metabolome", "metabolomics", "microbial", "microbiome", "mortality risk", "nicotine replacement", "novel", "reduced alcohol use", "respiratory virus", "trial design", "varenicline" ], "approved": true } }, { "type": "Grant", "id": "10591", "attributes": { "award_id": "1R01AI170839-01", "title": "Human Herpesvirus 6B in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome pathogenesis: temporal analysis of viral reactivation and immunity to elucidate cause vs effect", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22533, "first_name": "Christopher E.", "last_name": "Beisel", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-09", "end_date": "2027-08-31", "award_amount": 531652, "principal_investigator": { "id": 26618, "first_name": "Jackie", "last_name": "Cliff", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26619, "first_name": "Eliana", "last_name": "Lacerda", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1630, "ror": "", "name": "LONDON SCH/HYGIENE & TROPICAL MEDICINE", "address": "", "city": "", "state": "", "zip": "", "country": "UNITED KINGDOM", "approved": true }, "abstract": "/ ABSTRACT Our research project, entitled “Human Herpesvirus 6B in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome pathogenesis: temporal analysis of viral reactivation and immunity to elucidate cause vs effect”, aims to validate or refute the findings of our preliminary study on the role of human herpesviruses on the severity of symptoms in ME/CFS, and to determine if the virus reactivation is a cause or a consequence of the immune dysregulation. We will follow-up a larger number of consenting individuals (n=306), using our rigorous protocols designed to recruit participants to the UK ME/CFS Biobank (UKMEB). We have consent to re-contact UKMEB participants with ME/CFS (including those with a severe form of disease), and non-diseased controls (n=>500), with clinical assessments and collection of biosamples (blood and saliva). We will also recruit another comparison group, consisting of people with Long-COVID presenting with symptoms typical of ME/CFS (n=30), as well as people who did not develop long-term post-acute sequelae of COVID-19 after acute illness (Short COVID: n=30). The study population will comprise individuals from 18 - 60 years old, who have a diagnosis for ME/CFS or Long COVID with ME/CFS, as well as healthy controls and people who had Short COVID, in compliance with inclusion and exclusion criteria. We will perform a longitudinal analysis of people living with ME/CFS to determine the association and temporal relationship between HHV-6B DNA concentration and ME/CFS symptom severity, measuring viral DNA in saliva monthly for 6 months, alongside symptom scoring. To confirm that increases in HHV-6B DNA in saliva reflect systemic reactivation, we will measure blood viral RNA, DNA and protein, with the hypothesis that saliva RNA will correlate with saliva DNA concentration, and that all will increase together when ME/CFS symptoms are elevated. We will also measure frequency, phenotype and function of HHV-6B-reactive CD4+ and CD8+ T cells in people with ME/CFS. using flow cytometry, and will investigate the immunosuppressive effects of HHV-6B on antigen presentation in macrophages in ME/CFS using gene expression analysis. We hypothesize that HHV- 6B-specific T cells expand as ME/CFS symptoms worsen but are ineffective in for HHV-6B control, and we will test whether similar changes are observed in those with Long COVID in people who fulfill the diagnostic criteria for ME/CFS. Our goal, which stems from our successful pilot study, is to establish whether HHV-6B reactivation is causal in ME/CFS pathogenesis, and generate biological evidence which will inform targeted interventions such as vaccine development.", "keywords": [ "2019-nCoV", "Acute", "Adult", "Affect", "Antigen Presentation", "Antigen-Presenting Cells", "Bacterial Infections", "Biological", "Biological Assay", "Blood", "Blood specimen", "CD8-Positive T-Lymphocytes", "COVID-19", "Cell physiology", "Cells", "Characteristics", "Chemical Exposure", "Chronic Fatigue Syndrome", "Clinical", "Clinical assessments", "Collection", "Consent", "Cryopreservation", "DNA", "Data", "Data Collection", "Development", "Diagnosis", "Diagnostic tests", "Disease", "Endocrine", "Enrollment", "Etiology", "Event", "Evidence based treatment", "Exclusion Criteria", "Exertion", "Family member", "Fatigue", "Flow Cytometry", "Frequencies", "Funding", "Gene Expression Profiling", "Goals", "HHV-6B", "Herpesviridae", "Human", "Immune", "Immune response", "Immunity", "Immunologic Surveillance", "Immunologics", "Immunosuppression", "Individual", "Infection", "Interferon Type II", "Interleukin-2", "Intervention", "Knowledge", "Laboratories", "Life", "Long COVID", "Measures", "Multiple Sclerosis", "Mycoses", "Nature", "Outcome", "Participant", "Pathogenesis", "Patient Recruitments", "Peripheral Blood Mononuclear Cell", "Persons", "Phenotype", "Pilot Projects", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Prognostic Marker", "Proteins", "Protocols documentation", "RNA", "Recurrence", "Relapse", "Research Project Grants", "Role", "Saliva", "Salivary", "Severities", "Severity of illness", "Stress", "Symptoms", "Syndrome", "System", "T cell response", "T-Lymphocyte", "TNF gene", "Testing", "Time", "United States National Institutes of Health", "Viral", "Viral Markers", "Viral Proteins", "Virus", "Virus Diseases", "Work", "antigen-specific T cells", "base", "biobank", "clinical phenotype", "cohort", "comparison group", "coronavirus disease", "design", "diagnostic criteria", "digital", "epidemiology study", "follow-up", "inclusion criteria", "latent infection", "longitudinal analysis", "macrophage", "monocyte", "post SARS-CoV-2 infection", "recruit", "relating to nervous system", "saliva sample", "sample collection", "stem", "stressor", "study population", "vaccine development", "vaccine immunotherapy", "viral DNA", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "7153", "attributes": { "award_id": "3UH3DA044831-03S1", "title": "Oregon HIV/HCV and Opioid Prevention and Engagement (OR-HOPE)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 20583, "first_name": "KEISHER S", "last_name": "Highsmith", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-08-15", "end_date": "2022-07-31", "award_amount": 153900, "principal_investigator": { "id": 22947, "first_name": "Philip Todd", "last_name": "Korthuis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 765, "ror": "https://ror.org/009avj582", "name": "Oregon Health & Science University", "address": "", "city": "", "state": "OR", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 765, "ror": "https://ror.org/009avj582", "name": "Oregon Health & Science University", "address": "", "city": "", "state": "OR", "zip": "", "country": "United States", "approved": true }, "abstract": "/ Abstract Oregon HOPE COVID-19 Supplement Request Document not applicable to proposal.", "keywords": [ "Accreditation", "Adoption", "Adult", "Buprenorphine", "COVID-19", "COVID-19 pandemic", "Caring", "Chronic Disease", "Clinic", "Clinical", "Cohort Analysis", "Counseling", "Data", "Diagnosis", "Disease", "Dose", "Drug usage", "Electronic Health Record", "Eligibility Determination", "Emergency Care", "Emergency department visit", "Feedback", "Frequencies", "HIV/HCV", "Health", "Home environment", "Hospitalization", "Insurance Claim Review", "Interview", "Medicaid", "Medical", "Methadone", "Monitor", "Notification", "Opioid", "Oregon", "Patient risk", "Patients", "Pharmaceutical Preparations", "Policies", "Population", "Prevention", "Primary Health Care", "Process", "Public Health", "Quality of Care", "Quality of life", "Reaction", "Recording of previous events", "Regulation", "Rehabilitation therapy", "Relative Risks", "Relaxation", "Research", "Retrospective cohort", "Risk", "Rural", "Services", "Site", "Specific qualifier value", "Structure", "Telemedicine", "Telephone Interviews", "To specify", "United States", "United States Substance Abuse and Mental Health Services Administration", "Update", "Urine", "Visit", "authority", "beneficiary", "cohort", "design", "methamphetamine use", "opioid agonist therapy", "opioid treatment program", "opioid use", "opioid use disorder", "pandemic disease", "patient response", "patient safety", "prevent", "rapid technique", "response", "rural area" ], "approved": true } }, { "type": "Grant", "id": "6521", "attributes": { "award_id": "3P30AG021342-18S1", "title": "COVID-19 in Older Adults: A Longitudinal Assessment (VALIANT)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21854, "first_name": "BASIL A", "last_name": "ELDADAH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2002-09-30", "end_date": "2023-06-30", "award_amount": 753175, "principal_investigator": { "id": 21855, "first_name": "Thomas Michael", "last_name": "Gill", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Older adults with COVID-19 are much more likely than younger adults to develop severe disease and to die from their illness. Nevertheless, the best available data suggest that more than 90% of adults aged ≥60 will survive. Virtually nothing is known about the long-term effects of COVID-19 infection, but there are many reasons to be concerned that older survivors who were ill enough to require hospitalization are at risk of a substantial decline in their health and functional status. Normal aging involves a decline in physiologic reserve, and many older adults have other underlying vulnerabilities, including multiple chronic medical conditions and frailty. Hospitalized patients with COVID-19 endure long periods of immobility and social isolation. Upon discharge, there is the potential for limited access to community health care providers, such as physical therapists. Finally, reports have suggested that COVID-19 itself has the potential to cause long-term physiologic changes, including changes in metabolism. High quality data about these phenomena are needed to guide the development of targeted interventions for older COVID-19 survivors and to inform medical decision-making. Because the data available in the electronic health record (EHR) are not sufficient to assess the long-term health outcomes that matter to older adults, such as function, cognition, and symptom burden, longitudinal data about these key outcomes need to be collected from patients or their proxies. The Yale Older Americans Independence Center (OAIC), with a wealth of research expertise and a world-class Field Operations and Data Management Core, is uniquely positioned to collect such data. We propose to leverage this expertise to accomplish Specific Aim 1, the enrollment of a prospective cohort of 500 patients aged ≥60 years with COVID-19 from two large hospitals in southern Connecticut, near the center of the pandemic. We will perform a baseline assessment at or near the time of hospitalization and then follow-up assessments at 1, 3, and 6 months after discharge, with measures of physical and cognitive health, psychosocial support, frailty, quality of life, and, at the 6-month assessment, performance-based measures of mobility, pulmonary function testing, and a blood draw. This work will lead to a repository of outcome data that we will supplement with EHR-based variables and make available for use by other investigators. Specific Aims 2-4 draw upon the breadth of investigative and analytic expertise at the OAIC to illustrate projects to be undertaken with repository data. Aim 2 is an investigation of functional outcomes among critically ill and socioeconomically disadvantaged groups. Aim 3 involves work to characterize metabolic dysfunction among COVID-19 survivors, while Aim 4 is an examination of symptom burden. Because this study involves the collection of longitudinal data that would otherwise not be available, it will enable foundational research into the long-term health effects of COVID-19 in older patients.", "keywords": [ "Adult", "Age", "American", "Area", "Blood", "COVID-19", "Capsicum", "Cessation of life", "Chronic", "Cognition", "Cognitive", "Collection", "Communities", "Community Healthcare", "Connecticut", "Critical Illness", "Data", "Decision Making", "Development", "Diabetes Mellitus", "Disease", "Disease Outbreaks", "Elderly", "Electronic Health Record", "Enrollment", "Foundations", "Freedom", "Frequencies", "Funding", "Future", "Health", "Health Personnel", "Health Status", "Health system", "Healthcare", "Hospitalization", "Hospitals", "Impaired cognition", "Infection", "Institution", "Intensive Care", "Intervention", "Investigation", "Life", "Long-Term Effects", "Measures", "Medical", "Mental disorders", "Metabolic", "Metabolic Diseases", "Metabolic dysfunction", "Metabolism", "Modeling", "Muscle Weakness", "Obesity", "Older Population", "Outcome", "Outcome Study", "Overweight", "Patients", "Persons", "Physical Function", "Physical therapy", "Physiological", "Positioning Attribute", "Prospective cohort", "Prospective cohort study", "Provider", "Proxy", "Psychosocial Assessment and Care", "Psychosocial Factor", "Pulmonary function tests", "Quality of life", "Reporting", "Research", "Research Personnel", "Risk", "Services", "Severities", "Social isolation", "Subgroup", "Survival Rate", "Survivors", "Symptoms", "Syndrome", "Time", "United States", "Work", "aged", "base", "bone health", "cognitive function", "cohort", "data management", "data warehouse", "electronic data", "falls", "follow up assessment", "frailty", "functional disability", "functional outcomes", "functional status", "high risk", "improved", "indexing", "metropolitan", "neighborhood association", "normal aging", "older patient", "operation", "pandemic disease", "performance based measurement", "physical therapist", "recruit", "repository", "research study", "risk prediction model", "socioeconomic disadvantage", "virtual", "young adult" ], "approved": true } }, { "type": "Grant", "id": "10974", "attributes": { "award_id": "5R01DK128435-02", "title": "The B Cell Insulin Receptor in Health and in Insulin Resistance", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [ { "id": 26970, "first_name": "RAJATAVA", "last_name": "Basu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-12-15", "end_date": "2026-11-30", "award_amount": 565861, "principal_investigator": { "id": 24821, "first_name": "Dan", "last_name": "Winer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1784, "ror": "https://ror.org/050sv4x28", "name": "Buck Institute for Research on Aging", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1784, "ror": "https://ror.org/050sv4x28", "name": "Buck Institute for Research on Aging", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Obesity is a major global health concern. When people become obese, the body fails to respond well to insulin, called insulin resistance. This process can lead to high blood sugar triggering type 2 diabetes, though the underlying causes are poorly understood. We have shown that inflammation in the liver and fat are major causes of insulin resistance. Fat tissue in mice and people have increased immune cells, T and B cells, that cause inflammation. This net inflammation is one key link leading to obesity related insulin resistance. The current research proposal investigates how the B cell behaves during early and later stages of obesity. Interestingly, here we describe insulin itself as a major factor dictating the behavior of B cells in obesity. Specifically, we show that insulin binding to its receptor on B cells causes the B cells to proliferate, make inflammatory proteins and antibodies. This process contributes to establishment of insulin resistance since when mice are genetically engineered to contain B cells lacking insulin receptors, the mice show improved blood sugar levels when fed a diabetes inducing high fat diet for a limited time. However, this same pathway may also limit immune cell function during longstanding obesity. Indeed, we see insulin resistance inside immune cells with longer duration high fat diet, and compromised response to viral lung infection in mice with insulin resistant immune systems. Thus, we believe that insulin is one critical factor which primes the immune system to respond to danger signals in the environment and fuel its function. During establishment of obesity and insulin resistance, insulin boost activation and metabolism of immune cells to heighten inflammation when responding to danger signals; however, as the pathway becomes resistant, these immune cells with high basal inflammatory tone are crippled to respond to new challenge such as virus. This mechanism also likely explains in part why the obese cannot fight off viruses like influenza or SARS-2 coronaviruses. In this proposal we will use genetically engineered mouse models to map out how insulin controls B cell immunology during different durations of obesogenic diet. First, we will look at insulin’s capacity to control B cell inflammation, metabolic programming and antibody production. Next, we will understand how diet induced obesity communicates via insulin action on B cells to control blood sugar. This aim includes mapping out insulin receptor docking sites on immunological target genes. Then we will characterize the immunological consequences of immune cell insulin resistance during lung virus infection in a mouse model of influenza. Finally, we will determine the relative mechanistic roles for obesity related danger pattern signaling in contributing to the insulin resistant B cell inflammatory state. These experiments will give crucial new insights into immune cell influence on obesity, and how obesity potentially cripples immunity, which has relevance to many conditions, including lethal viruses such as our current pandemic.", "keywords": [ "2019-nCoV", "Activities of Daily Living", "Acute", "Adipose tissue", "Adjuvant", "Aging", "Antibodies", "Antibody Formation", "Automobile Driving", "B-Cell Activation", "B-Lymphocytes", "Behavior", "Beta Cell", "Binding", "Blood Glucose", "Brain", "COVID-19", "COVID-19 risk", "Cell Nucleus", "Cell Survival", "Cell physiology", "Cells", "Cellular Metabolic Process", "Cellular biology", "Centers for Disease Control and Prevention (U.S.)", "Chronic", "Communication", "Coronavirus", "Development", "Diabetes Mellitus", "Diet", "Disease", "Docking", "Environment", "Fatty acid glycerol esters", "Frequencies", "Functional disorder", "Genes", "Genetic Transcription", "Genetically Engineered Mouse", "Glucose", "Health", "High Fat Diet", "Homeostasis", "Human", "Hyperinsulinism", "Immune", "Immune Targeting", "Immune system", "Immunity", "Immunoglobulin G", "Immunologics", "Immunology", "Infection", "Inflammation", "Inflammatory", "Inflammatory Response", "Influenza", "Insulin", "Insulin Receptor", "Insulin Resistance", "Insulin Signaling Pathway", "Knockout Mice", "Knowledge", "Link", "Lipids", "Liver", "Longevity", "Lung", "Lung infections", "Maps", "Metabolic", "Metabolism", "Mus", "Muscle", "Non-Insulin-Dependent Diabetes Mellitus", "Nuclear Translocation", "Obese Mice", "Obesity", "Organism", "Pathogenicity", "Pathway interactions", "Pattern", "Persons", "Play", "Process", "Production", "Proliferating", "Proteins", "Receptor Signaling", "Reporting", "Research Proposals", "Resistance", "Risk Factors", "Role", "Severe Acute Respiratory Syndrome", "Signal Pathway", "Signal Transduction", "Site", "T-Lymphocyte", "Time", "Tissues", "Toll-like receptors", "Viral", "Virus", "Virus Diseases", "Visceral", "Work", "cytokine", "diet-induced obesity", "experimental study", "fighting", "global health", "high risk", "immunoregulation", "improved", "influenza infection", "insight", "insulin signaling", "mortality risk", "mouse model", "novel", "novel therapeutics", "obesogenic", "pandemic disease", "receptor", "response" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1419, "count": 14184 } } }